BIIB037 (aducanumab) is a once per month IV infusion that was FDA-approved in June 2021, but Medicare did not reimburse it due to a feeling that another study was necessary to prove efficacy, hence the ENVISION trial. The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. Aducanumab is a monoclonal antibody that removes amyloid plaque which is associated with neuronal degeneration and Alzheimer’s disease.
Qualified candidates must:
- Be 60-85 years old
- Have known or suspected Alzheimer’s disease
- Have a study partner that can assist you and sign consents